Please login to the form below

Not currently logged in
Email:
Password:

Hemophilia

This page shows the latest Hemophilia news and features for those working in and with pharma, biotech and healthcare.

Roche highlights Hemlibra data as key FDA date approaches

Roche highlights Hemlibra data as key FDA date approaches

Expanded use would see revenues take off

Latest news

  • Pfizer enters late-stage haemophilia B gene therapy trial Pfizer enters late-stage haemophilia B gene therapy trial

    begin our Phase 3 programme evaluating fidanacogene elaparvovec for the treatment of hemophilia B. ... We look forward to the opportunity to continue the progress achieved by Spark Therapeutics for patients living with hemophilia B.”.

  • More encouraging data for Spark and Pfizer’s potential haemophilia B cure More encouraging data for Spark and Pfizer’s potential haemophilia B cure

    These data are presented today by Spencer K. Sullivan, M.D., haematologist and clinical investigator,  Mississippi Center for Advanced Medicine, at the World Federation of Hemophilia (WFH) World Congress in Glasgow,

  • Shire to customise MicroHealth's app for haemphilia patients Shire to customise MicroHealth's app for haemphilia patients

    MicroHealth, a digital health company co-created by a hemophilia patient, originally launched its app in 2011 to help improve haemophilia patient care and outcomes. ... I wanted to develop a tool that would help streamline hemophilia care to produce

  • Novo launches haemophilia tracking app Novo launches haemophilia tracking app

    The other unusual feature is the way it syncs with Novo's haemophilia inhibitor website Changing Possibilities in Hemophilia, where members can access a range of reporting features, such as treatment

  • R&D news in brief

    In one trial, the safety results, presented at the World Federation of Hemophilia conference, found that BAY 79-4980 showed no significant differences compared to Kogenate FS.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Changes at Oxford PharmaGenesis, Reynolds-Mackenzie and more Changes at Oxford PharmaGenesis, Reynolds-Mackenzie and more

    Over the past year Hyne has contributed to conferences and meetings including the World Federation of Hemophilia (WFH) congress and the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    As we head into 2017, we are fully focused on achieving several important catalysts, including rapidly progressing our hemophilia B programme into late-stage development and advancing our gene therapy candidates

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics